Last reviewed · How we verify
NCT06147908
Clinical Trial to Evaluate the Pharmacokinetic Characteristics of DW5221 and DW5221-R
Phase 1 trial testing DW5221 in Apetite Stimulants in 54 participants. Completed in 17 November 2022.
26 October 2022
Quick facts
| Lead sponsor | Daewon Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 54 |
| Start date | 1 July 2022 |
| Primary completion | 26 October 2022 |
| Estimated completion | 17 November 2022 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
Conditions studied
- Apetite Stimulants — all drugs for Apetite Stimulants →
Sponsor
Daewon Pharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 19 to 55, male only, with Apetite Stimulants. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A bioequivalence study to compare and evaluate the pharmacokinetic characteristics and the safety after administration of DW5221 and DW5221-R in healthy adult m ale volunteers
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Drug Nanocrystals in Oral Absorption: Factors That Influence Pharmacokinetics.
Macedo LO, Masiero JF, Bou-Chacra NA. · · 2024 · cited 8× · PMID 39339178 · DOI 10.3390/pharmaceutics16091141 -
Comparison of the pharmacokinetic characteristics and bioequivalence between two nanosuspension formulations of megestrol acetate in healthy Korean male subjects.
Park SR, Hwang JG, Jeong SI, Choi YS, et al · · 2024 · cited 1× · PMID 38586120 · DOI 10.12793/tcp.2024.32.e6
Verify or expand the search:
- PubMed search for NCT06147908
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Daewon Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07364851 — A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421-T1 and DW4421S-T1 in Healthy Adult Volunt · Phase 1 · not yet recruiting
- NCT07349589 — Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers · Phase 1 · not yet recruiting
- NCT07364877 — A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421 and DW4421S in Healthy Adult Volunteers · Phase 1 · enrolling by invitation
- NCT07343245 — A Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDs · Phase 1 · recruiting
- NCT07319559 — Clinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect of Food on · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06147908 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Daewon Pharmaceutical Co., Ltd.
- Last refreshed: 28 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06147908.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing